ENTA - Earnings call transcript Q1 2020 | Enanta Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Enanta Pharmaceuticals First Quarter Financial Results Conference Call. At this time, all participations are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions]

to conference like to now would hand over the Ms. I Director of Miceli, Investor Carol Relations. ma’am. ahead, go Please

Carol Miceli

Thank thanks quarter Erica, our release issued you, and and website. with The this today our news afternoon. fiscal available first is financial was for results on joining us

our Enanta’s On Mellett, senior is management CEO; today and Officer, call Jay Luly, team. Financial the and other President Dr. Paul Chief members of

these certain which SEC. be pipeline may XX-Q that reports research want begin our to to remarks, remind risks making with could forward-looking our which we the assumptions that most and and and projections, we control filed those results expectations statements, with Before our differ developments risks and and of we will cause include our materially other plans our of statements. with and our you to involve periodic all formal respect is recent beyond in Form financial actual from description A development

any any Enanta not call. forward-looking to this during undertake does made statements obligation update

the to Luly, Jay and I’d President now Dr. to call over CEO. like turn

Dr. Jay Luly

everyone. Good Thank afternoon, you, Carol.

today’s NASH On and clinical HBV discuss I with begin milestones development recent only XXXX. today. for EDP-XXX, development upcoming in look I’ll and to for compounds, lead our the call, progress on in clinical N-inhibitor will RSV, our RSV

is and severe safe RSV no elderly and mortality compromised immune and which currently the is therapy. respiratory infants, adults, there a condition infection associated morbidity with and in significant a effective for

of to five to EDP-XXX of approximately either we a evaluated study is course days. study up of The the effect or key EDP-XXX, measured XX-day which a progression endpoint. placebo-controlled Any of is the subjects initiated will viral of years, assessment evaluate of milligrams placebo Phase XX XXX RSVP, to named EDP-XXX be enroll study as to infection see efficacy objective over period. by randomized, end our of for the the symptoms randomized the age At observation on of of Xb receive clinical RSV XXXX, the study, primary designed secondary double-blind XX this

report visit identify the who’ve to prompt Identification on-site appears which have it months RSV that American most PCR RSVP has Unfortunately, that their symptoms approximately had RSV XX to two confirmation we in of season to the is pleased group of We’re North patients been providing peaked winter adult in RSV able been site. that an aided earlier infection, this December, than many started cold hours of been study by this outpatients, testing. which one years. we’ve within like in by to

have are first fewer to study a and have in As now than to sites and into result, with enrollment have all half to the we therefore expected, goal the we XXXX. of southern planning cases in seen hemisphere RSV continue the continue data

RSVP addition of In X this patients with initiate concurrent have pediatric the to year, end plans the this we and Phase additional studies patients study, by also transplant study. to announced in

it attacks viral program, month, We therapeutics RSV, also success human we approach N-protein machinery. metapneumovirus, is as as virus’s against with chance our because HCV ongoing the our best success inhibitor continue last the to introduced with for newest our for RSV, seeking known replication such drug believe and on Building discovery our program represents that infections which hMPV.

in as causes immunocompromised elderly, patients. and that upper XXXX young tract the well lower asthma, in identified pathogen a infections as and in COPD, children and respiratory is hMPV

nanomolar against current During optimization perform of will leads virus. XXXX, inhibitor this to we our continue

HBV. Now, let’s shift to

infrequent doses patients multiple SAD study two and up of of will aim activity a Overall, findings single of ascending of the part X subjects safety ascending core HBV in our Our as others announced dosed EDP-XXX novel and our in HBV HPV adverse from the is subjects, volunteers. with with program CAM. abnormalities. of we the Treatment intensity. healthy emergent chronic X there safety, lab adverse healthy portion individual class events, ahead due study were The EDP-XXX Phase safety moving in No this randomized pharmacokinetics data positive results nicely. one one is in tolerated with assess profile. was no days EDP-XXX to of antiviral and favorable healthy part EDP-XXX EDP-XXX And to or in while and doses inhibitor, sometimes by XX the were today to to placebo-controlled events pattern to and EDP-XXX MAD infection. discontinued tolerability was referred assembly evaluate of significant capsid first-in-human double-blind the or for mild nuc-suppressed modulator well lab

the Additionally, level of blood profile or was once daily supportive dosing. pharmacokinetic fully

being plan study Following We XX HBV in support infection study patients, a days. a with total three suppressed reverse-transcriptase Enanta nucleoside dose these promising clinical cohorts of which among further results, nuc-suppressed of are for EDP-XXX evaluation to is initiated XX has dose in drug patients treatment. with with HBV patients, chronic subjects enroll that escalating these

study to XXXX. of quarter goal calendar the Our is have data in from this first

our potent volunteer has been abstract accepted study by Liver antiviral series activity levels An Next mechanism. to patients for for blood or the to presentation HBV that on characterized of referred and as and virus promising was selected who therapy portion plan in separate for preclinical EDP-XXX and the we as of are at International this lead recently data have our initiate compounds quarter, EASL. HBV are excitement of EDP-XXX of a also in from who study not healthy viremic. the also Congress support high their

data additional in for tuned stay April. So,

our to program. NASH Switching

of been ARGON-X oral EDP-XXX, that Xa proof the We FXR candidate study an our EASL. to are concept of Phase at presentation pleased as announce has lead agonist accepted

milligram and plan milligram study biopsy fibrosis. doses in study We The of will double-blind we with X endpoint analysis to improvement approximately NASH, scene to plan worsening initiate biomarker to dose NASH. than more a evaluate XX-week in dosing the of signals milligram which that study. of ARGON-X pruritus without NASH. potential X further information use include X.X for subjects other in early stronger ARGON-X in of of this placebo-controlled of to at the NASH of efficacy Xb study with Phase with be study combinations than the demonstrating quarter. aim mechanisms fibrosis study be interim the XX-week EDP-XXX and seen primary worsening next milligram We at and/or in X.X less will by resolution XXX ARGON-X, expect The without will generate in randomized, quickly proven

FXR EDP-XXX in reveal a data as target high that that Also on in differentiated on candidate. Preclinical our NASH today. profile tissue program, potency distribution, EDP-XXX development follow-on any with Enanta has clinical agonist than identified published FXR greater its delivers along

the This FXR in at the April. and drug Two FXR drug minimizing compared EASL that we Last development. compelling agonists demonstrate in and preferentially data namely delivered to while that involved targeting in levels conference presented in targeting have models and month skin. JPMorgan data the at of presented EDP-XXX and plasma showed activity, to other tissues will the abstracts preclinical in intestine been high EDP-XXX conference, potency characteristics tissue tissue be EDP-XXX liver accepted on

non-targeted highly FXR for pruritus agonist will is and believe EDP-XXX tissues, highly liver potentially targeted mediated and potent by like the receptors that less and pruritus, or allow doses We thereby a FXR lower levels reduced FXR in having reducing at intestine. drug

to to X initiate in plan and of half in a Phase calendar mid first study the EDP-XXX We data XXXX XXXX. have of

to announce we expect INTREPID in has completed PBC study top of EDP-XXX by and data dosing, the Lastly, quarter. early next line

of results EDP-XXX study Xb in of of and keep So, for new results at EDP-XXX Phase study of HBV EDP-XXX, our your Phase X PBC creation initiation patients, our eye out of in X the EASL, midyear. Phase all presentation viremic by X of of EDP-XXX Phase

I’d today. like key summarizing by from close of couple takeaways a to

the initiate in the second PK patient HBV year. of the in leading we First are RSV two that another And is had later the America, have good lead inhibitor of additional populations part with this second, and patients. HBV study EDP-XXX in volunteers, of North progress. study good we safety us healthy core RSVP to despite all advancing RSV to start This for season results the plans and studies vagaries nuc-suppressed

call to quarter. Paul Paul? to discuss our turn for the financials over the now I’ll

Paul Mellett

Thank you, Jay.

Enanta our royalty product the first period like for on reporting a remind $XX.X In quarter compared XX, XXth reports to This XXXX. on revenue sales. of September million global everyone same that of for the HCV $XX.X fiscal AbbVie’s results ended revenue XXXX. we to consisted are was I’d December revenue earned entirely in million total Today, year total schedule. quarter, and

XX%. been sales. approximately sales After be quarter product XX% AbbVie sales and global sales Royalty revenue at a rebates, February number had approximately royalty royalty rate for X.X% a historically total calculated of XX%. of of have their XX% contractual rate of HCV certain reported HCV recording MAVIRET VIEKIRA on AbbVie’s which of And Xth. discounts on adjustment will for the is

our reminder, highest royalties ended for the Therefore, lowest calculated on royalties fiscal our calculated royalty quarter calendar rate XXst, year a coming March for royalty be ending quarter fiscal at XX%, and are will year. will December XX calculated first our royalties a basis. our our in as As be tier rate, fiscal

You XX-K. in XXXX can review Form tier schedule our royalty our

decrease for the in $XX.X Moving PBC Research three XX, December totaled expenses with associated HBV. months on clinical $XX.X ended RSV, XXXX. wholly-owned NASH, progression to our and The to costs expenses the XXXX. of was timing of primarily period the due clinical million the in for same development to and compared million, trial programs

to quarter in for the decrease General administrative expense was and comparable $X.X a XXXX. the million, slight quarter

XXXX, expense months million the XX, Enanta reflecting the in ended recorded expense income compared before taxes. income period for income XXXX, same of for the tax tax in -- million an $X.X reduction to tax December income of income three in $X.X

The approximately research in months Enanta’s period XX, foreign-derived corresponding for benefit approximately For to XX%, as income. ended from federal the the effective was rate driven in and both, well compared development royalty by a XXXX. was three December rate reduction tax as XX.X% credits, XXXX,

diluted for XX, to million income period the $X.XX of a was ended corresponding $XX XXXX. three months the net December share, common Net compared $X.XX million, share, XXXX or per or income $XX.X per diluted common in

available ended securities, in will approximately million financial Form release year details from $XX Enanta of cash marketable XX-Q Further be an on in quarter, million. are $XXX and XXXX and report our our approximately available end press when of quarterly our balance increase the with million fiscal filed. in $XXX

lines turn like the and operator to the now to open call back the up for questions. Operator? I’d

Operator

first is Instructions] [Operator RBC. question Abrahams Your with from Brian

Brian Abrahams

know, shaping off the bit little a mentioned be selection to more was the there. -- design XXX had later? in you’ll you pediatric First get as getting program. wondering guys the studies to a year. thinking are RSV follow-up. this duration potential how going could studies like look underway about about the transplant that talk on those and I I particular, elements dose And you then, later I you on how be what’s going And if you potential

Dr. Jay Luly

Yes.

thanks details Brian. of right So, working now question, for team The is those of on both the fine studies. the

call premature two have new studies as into a say, report bit progresses, So, it as to then. RSVP it’s little on more on the I’d exact I’d gels, say, design we’ll year lot this and the say to we’ll about a these get more that. of

Brian Abrahams

the with volunteer then, well you sounds more PK a Phase therapeutic I and you elaborate with might able differentiated of on Okay, the wondering development? your B to what to that study along this least the guys hep just being anything, from glean it on And healthy bit is Thanks. X like you’re and if your maybe Phase was X at same that safety, from that fair enough. the moving And support window little in observed view program could study for respect class in others agent. thoughts XXX.

Dr. Jay Luly

on of background Well, just too XXX first. little with certainly, bit start I’ll a a preclinical

vivo including but XXX, profile, time worked candidate vitro a a terms preclinical to in long certainly first pretty profile, picked than core has of Everything multiple it profile, preclinical had too. of identify believe a and it having and where or inhibitors. we good capsid in So, across not better virology, pharmacokinetic great clinically it. that looks it in about different profile We this the chance species a suggested strong capsid generation that only

and well-tolerated, But, at as So, remarkable to a any PK viral. when suffice findings. the status the of importantly, presented around you’re of that we’ll safe, it formally generally in was it EASL. all lot have really nothing terms know, say, important is again, details looking at you And

virus. a forth give And good amount us on so, troughs got, good and would of we pressure think exposures the good and we’ve so that

is this study, it’s XX-day a So, and in healthy.

with EASL. lay definitely it the out strong. the are at results we’ll all very So, clearly details But,

Operator

Eric Joseph question is Morgan. next with JP from Your

Eric Joseph

that thinking Phase it would XXX. over Xb you first nuc-suppressed guess, couple XX-day in MAD Can study about I’m A for talk conversion a of me, antiviral portion at correctly, pgRNA? you assessing at heard efficacy? study If Are XXX objectives little us trial I you on through treatment the about portion? just a looking How in the this period. surrogates for study I sort of a or walk sort activity? patients. the are looking you Can be

Dr. Jay Luly

remind that Again, Phase Yes. Xb I’ll a you is XX-day this study.

of term things short at on comment let Nathalie be principally primary it’s safety related study where other to other endpoint. So, to looking But, be we’ll a some studied. as I’ll the aspects

Nathalie Adda

the first-in-man second I just echo think what So, is said, this study. part to Jay

in key, PK nuc-suppressed and safety, objective. secondary the obviously Xb, subjects, primary be we looking the For are will

at other looking. companies all would in point We are be also will say the looking field that exploratory I that end

to viremic are considered so endpoint or Just exploratory remind still far all that, patients those you essence. in nuc-suppressed in

as So, are looking we would obviously and study. at finalizing something report we that DNA, we HBV as other. RNA HBV such And will the be

Eric Joseph

there. I reduction powered separate what just question design design or to to versus about power terms I’m comps trial trial on revisit assumptions and to programs at in thinking Thanks. that’s time curious in what the looking the to appropriate talk no -- whether just also -- study longer maybe time you’re looking detect RSVP the symptom at the are of is resolution? wanted And symptom you if of study. about know the just And term treatment? total empowering a not whether at flu to whether of terms some useful looking antiviral Can symptom

Nathalie Adda

part. study. completely clearly first you RSVP once the I can So, understood question Maybe not sure the part. heard power second I your address I I think, of about very first repeat I’m the the

few think, core times that So, study. a or question had we I regarding RSVP the

understanding and We have, know, time. our run we study was ecosystem patient received used, a drug context identify the you Clearly, what in the in design our analyze. to over as was placebo and challenge far as really and challenge that of the who as evolving

I’m way obviously not of symptoms at more ready disclose data. the study, we will XX it’s course we to over be please? what looking when question, conduct. yet the time your how as difference know, responding. can to study you of power present I today. onset indirect seeing But, I the second that’s I But, relevant of part days me progression completely think it’s Would you of offer from of really mind

Eric Joseph

longer studies I’m EDP-XXX? And a potentially term about at is studies. whether set to comparator RSVP antiviral to development And endpoint influenza curious in of the in time for in that an as at Thanks. thinking development pivotal the wondering that specifically of I’m reason asking useful is whether symptom the you’re to know is used of question Sure. the look study. looking resolution that the

Nathalie Adda

I your Yes. Thank you. question. appreciate

have other many we’ll studies series flu There’s to endpoints and of relationship looking the of to There resolution, looked time to at as symptoms. a endpoint symptoms pollution. to analysis details, detailed obviously, that at understand more be in more time patient key obviously of be So would all progression. we secondary

Operator

from is Capital. Our with Rahimi next Roth question Yasmeen

Unidentified Analyst

Thanks Yasmeen. for for taking question. on my Paul

confirmation intervention? about the loads ask window can to -- patients’ RSV range And again if the be optimal Can about and I you first, wanted for just quantitatively of used RSVP. So, fall more determine the talk optimal for in to the viral PCR study? about diagnosis

Nathalie Adda

a of PCR window, the the And confirm side. we patient which within clinic the So, afterward. [indiscernible] the at it’s also be at using hours centralized up when show there so XX a the we PCR will are and do that

Unidentified Analyst

on Okay. the And what Can portion of question. give profile look one study? more viremic like the you color in patient just more would the of next some EDP-XXX

Nathalie Adda

time, Say more that please? one

Unidentified Analyst

the next viremic patient look for profile study of the EDP-XXX what the like? wondering was in I would portion

Dr. Jay Luly

of the for for XXX HBV. The -- profile

Okay.

So, the HBV. you to I -- didn’t switched

that are any country. the have there level washing viremic. be I think of a patients they window level that So, treatments will elevated or HBV either don’t received show than an to but they treatment, nuc-suppressed be of who treatment HBV they higher receive could have DNA of could DNA you Obviously where naïve at

Operator

from next Wolfe Akash with is Tewari question Your Research.

Akash Tewari

they like that. get to So, maybe a in trial, you the little flu Would something a load trials? on or on the love RSV why chose Phase benefit endpoint versus X, maybe viral AUC bit some some maybe or detail symptom color your on primary Phase Xb use as baseline of

have you protocol, And any of similar of previously patients hours there -- think that treatment the say it timeline? patients powering for presenting you’re I that within your Are mentioned will in X. kind -- Phase seems tricks present onset. be was you’re trial like XX the to treatment that mean, that that using I are to window symptom ensure had Additionally, to going actually within finally, you to that

XX% Is you So, I enrollment, ‘XX? the was could getting think that powered. that chance now trials much. so pushed to Thanks your a first around that increase there half

Dr. Jay Luly

don’t So, tricks. think special are there there, any I

of But, we’re window time you know. in I they only terms Could news have as say were your the question Obviously, of the think, of they’re first and the question, symptoms. good your first lots symptoms. part of people what in we repeat is, to people rely with again? taking seeing present they reliability that people coming we on who can the within first

Akash Tewari

absolutely. Yes,

symptoms. secondary and at we J&J’s RSV pilot a they’re So, and clinical their X, lot think trial looking at endpoints, were viral outpatient primary Phase I like kinetics, of looking

endpoint. of wiggle than you these So, are at? interesting other that as it Does countries benefit a AUC exploratory why room somehow it’s symptom some endpoint, endpoints give primary an your specifically, looking bit

Nathalie Adda

the as total study. of and very think, into the look the endpoint thorough I challenge far also driven the to choice symptoms as score primary AUS understanding the our mainly was of to analysis

As looking be for for in we that will our we endpoint the of worked a for with better that AUC score are statistician, symptoms what we context saw study.

Dr. Jay Luly

an It’s be because points, get also diaries easier will cetera. reporting et data in basis outpatient to symptoms people more on

So sampling outpatient more can on basis get an practical data from study, that way? you a

Nathalie Adda

site, went Just a about that Jay work that said to obviously them. mean, to lot trick. the what complement come I want of site to see the educating educating into there’s patients and

family emergency center with COPD. patient asthma, using are with care, practice, We allergy,

So, that’s we attract understanding have for launched of a large with clear study. to campaign criteria trying the patients eligibility

we were within successful So, to window. in be able attract symptom sense our that patients to with

Akash Tewari

And just a quick question.

on you Phase trial chance is more total versus number with might of like at a suddenly that your the more other the line of delay any RSV Xb in patients in enrollment, studies? the Given there RSV flu so be looking side, you’d increasing something have trial

Nathalie Adda

There the is enrollment no plan to number. increase

Operator

Your JMP next Bayko with Securities. question is from Liisa

Liisa Bayko

cuts you’re doing Just wondering be data the thought some if that RSVP in before to needed adult going you into pediatric. study. moving any I patients of interim

all wondering to just And this on still time at of that’s you’re if going the work. how So, end year? start to

Dr. Jay Luly

They’re an interim be won’t and not interrelated, there really cut.

information who So, studies in that these wealth be and would run speeds all concurrently. of take our study expectation is have how drug thinking the the that dose we ultimately. about all we partly into we’ll received But, our adults have the

Liisa Bayko

Okay.

data need the the to the doesn’t before in population pediatric FDA study? adult So see starting

Dr. Jay Luly

No.

Liisa Bayko

then a just that? curious bit little mentioned talk as profile I you little of about I’d think more be more the a about And it. and was bit you differentiated. maybe could Okay. Got it XXX, differentiated

Dr. Jay Luly

Sure.

to FXR So shifting gears now.

in saw and FXR looking the trying with know you ARGON the X. things. as molecule would than the spent more surprised study other that follow-on time all we saw pruritus we the that potency we we characteristics expected doses in of us from was we of What XXX Obviously and whatever We Phase lot to information selectivity used, are optimize at kinds have could. XXX So agonist. a of

that these then about to thinking is it forward for way a about us better going how so understands that XXX it target, the gives for use XXX, of FXRs what’s and others of target than became we’re path really understanding tissues, how is nobody independent clear absent XXX sort tolerability was the various have confirmed thinking mechanistic pruritus but sort to that And nobody is certain to on the we so but we that is lipids of pruritus we approaches to that more not what needed target, pruritus, having it with is that really part confounding mechanism. it, of reduce perhaps do the so in to figure did how -- took that out The try knowing improve thing upon. could is in other off of seen on causing it

down a So is to potency number could possibly drill one you good is do. the potency as

worked that side more we generated on that’s JP potent it’s but based and the most development the potent put one agonist Morgan out on any FXR. we’ve we worked So side EASL, the that FXR by at at have data worked -- is initially, other data today. very versus you’ve and It in we’ll very, a

So one, because good you amount takes of reduce punch. will that the to drug deliver the number that’s it

are for we in in would for NASH. the know a of that efficacy compound in be receptors we that So in the looking sites the liver intestine of and FXR also terms

because be high something that drug if in well. had potent at And you of have it would circulating to the and kinds the the skin and of to the going we minimize might it these be you body obviously around so specifically FXR interesting tissues liver we levels plasma not and all are aimed as drug for exposure other in directly addition plasma hopefully potent for and we to exquisitely and skin, making less know, not else intestine thought

the So potency. very, very of good twofold combination having really it’s

only where were could only happen. and go the -- only having drug other we’ll of things we the the need amounts directly drug be sites then were that the where don’t small sites that we at to were So very and drug hopefully -- dosing drug need just not

hoped, a there if that thesis out it today. actually, and would We if benefit scenario, learn might is to as it have not it’s amount we scenario by in but a and of or But liver we luck we super scenario other with of that narrow that’s XXX where other up and it’s some we’ll exploring. any X are fair of Phase come is FXR this chance mediated think or on we half what super, track be that’s can receptors in out the FXR and intestine, the next may we’re with with be, only the -- coming of the have of mediated, achieved So to potent FXRs year. start inside that Phase the play bad the data the X middle sort in there pruritus our version -- of with if the study a year then FXR first

straightforward plan, chemical pretty the EASL, a excellent field. entrant looks polished a into a but like it’s it it’s -- So molecule an profile at it’s more

Operator

Baird. with Skorney Brian from is question next Your

Brian Skorney

seems dosing you and walk the chimeric I pretty the target high topping despite EDP-XXX. guess to patients? in you in how doses? translating mg a Can liver on just activity? going target have per at that maximize want into through how to thought date escalation results kg isn’t you just Any mouse think If antiviral model, dose look think about I dose to on out us really it like first where to here about the to

Dr. Jay Luly

that robust is dose in numbers humans. strong experiment wouldn’t I -- model rodent to effect. antiviral in very a into that wouldn’t at response What translate and I -- the a look very Yes.

anti-viral model. it’s most fact, that effect In anybody the in has that reported robust

dose when into out whole lay a then. good -- good you get a in I get too whole time will but terms comparing So, thinking wouldn’t did we again at look we the that milligrams much and about the to kilogram actual to -- data and of use we’ll escalation wouldn’t I we’ll be a doses in the that it at humans. rodent at translation set work spend to doses take it able per look and EASL

Brian Skorney

screening And And for the I screening then primarily and RSVP you patient symptoms first RSV flow patients just then patients have how Are the with question in us on many a in for screening with just with remind if respiratory works you in ask respiratory could screening you study? do for study, on just how can screening RSV influenza? here? any in versus coming data out symptoms them the

Dr. Jay Luly

Yes.

people within flu PCR for XX an for take flu A again you’re flu and hours versus RSV symptoms. candidate. negative potential and for of done. positive then and RSV There’s in-office you flu that’s negative look We So. a are for B, or B A we if

RSV. is there flu there out know than more You there is

again, So you’re going in test to which that coming see straightforward within more people we’ve seen a presentation screens, straightforward speaking, XX of it’s worth many hours, people a in these but in generally of coming in, that window.

Brian Skorney

get it a a real to what world at and number kind of seasonal in of get percent as guess does, flu this like reasonable a as we to offers? moves the could a of trying for see I’m RSV obviously the commercial is comp sort feel what to assume of Tamiflu sort setting, treatment. I’m to into eventually trying what I if if

Dr. Jay Luly

every robust know doesn’t you is The -- so as scale routinely what every not people bit be seasonality this It is be really and -- it patient routinely might to year. is seasonality correlate season. the RSV Yes. changes different perfectly lower There a flu it, just and season a overarching little high high more I part as testing fully a as not and probably clinical on flu, broad because don’t not as practice. basis done are think again numbers know yet could but

the it is the don’t drugs because test not So exists it’s and don’t in that part exist.

typically to cases in be the a which order general general that’s demographic RSVP an aged they what severity very study, outpatient in the once are fraction test. At are. will different just again RSV Also of in happens are the are what of drive but are every know So infection. patient out every, RSV don’t gets infection the down it’s so people and a question We peds are question those often that It’s time about in question what a peds they they or three. they get by -- a adults significant peds study. of thinking ultimately two peds the are they adult all is fraction of the numbers, in to every what

Operator

Patrick Your Instructions] Trucchio is Capital from with Management. question next Berenberg [Operator

Iris Long

Hi. for on Thanks Long my Patrick. This for taking is question. Iris

patient can would a into if evaluate so, EDP-XXX, directly sufficient? having or elderly trials in you expect And in pivotal or is finally, population to you for And to two you Thank you you. two if the pivotal pivotal So you anticipate would trial regarding one run this tell drug then would patients? trials patient maybe us population? trial X running another Phase each move anticipate

Nathalie Adda

Thank your I questions. and are they good address you that, can question, for

So peds. I next are informed transplant really will now in and studies our that the we population the We need. that unmet be for medical have think know those

study of we there guidance I question. that’s is or FDA issued at We the be are for focus a we the drug. population regarding next one think will excluding the not elderly, we a EMA, or peds. question to understanding future obviously. also you for if to pivotal don’t your will good good and for the They when be usually into the next transplant But RSV. study, on Today, clear need two looking very look the think plan a target if are I do, To of register now pivotal like

in going we of program. it’s authorities interesting be as engage to progress our think to moving are regulatory I

as obviously further. know will we progress we more So

Iris Long

you data can got would And it. a consider Okay, regarding result? top be us highly line then successful to what Thanks. tell RSVP, you

Nathalie Adda

And you put it, attract see understand understand the lower simply maybe p-value, interesting I’ll RSVP to field, that I this to a we I patient And and severity for progress then need the also feasibility and tract understand to think infection. we in is happy guess, and trying I can with to nasal the of how make is respiratory be per us can million for what can with it soon you if to an treat study think that. Well, symptoms practice. nice present the to we

cure RSV, winning have for will if there a be you product. think of I good half probably

Operator

Carol call at And turn there I’ll are no this back over Ms. the further time. Miceli. to questions

Carol Miceli

today. for Thank you everyone joining us

have you in you. further office. the us give a If feel questions, to free Thank any call

Operator

conference call. Ladies and gentlemen, concludes you for participating. today’s Thank this

may You now disconnect.

Enanta Pharmaceuticals (ENTA) 6 Feb 202020 Q1 Earnings call transcript